Molecular Pharmacology’s Recent Advances: From Targets to Therapeutics
Keywords:Therapeutics, Personalized Medicine, Drug Design, Precise, Revolutionary
Modern pharmaceutical development is based on molecular pharmacology, the dynamic intersection of molecular biology and pharmacology. This review article deftly navigates current developments in this area, outlining crucial developments in target discovery, drug design, therapeutic applications. The complicated relationships between medications and cellular components are dissected with remarkable accuracy by molecular pharmacology, revealing the complex mechanisms behind their effects. This investigation covers a range of medication classes and reveals the associated networks controlling their therapeutic effects.
Target identification is accelerated by high-throughput approaches like CRISPR-based screening, accurate drug design is aided by structural biology’s illumination of drug-target interactions. Drug-receptor interactions have a significant impact, signaling pathways-those molecular highways of communication-are dissected to reveal this. Pharmacogenomics and the use of biomarkers are at the core of the emerging field of personalized medicine, enabling therapies customized to individual profiles.
Emerging technologies like nanotechnology and gene editing are changing drug delivery and targeting in the far future. Therapeutic applications in a variety of fields demonstrate the molecular pharmacology’s transformational potential through directing cancer immunotherapy, therapies for neurological diseases, more.
Interdisciplinary cooperation emerges as a lynchpin for future advancement amid the scientific crescendo. As molecular pharmacology makes unstoppable progress, its comprehensive understanding of disease pathways opens the door for transformative medical paradigms and ushers in an era of customized therapies.
Adams, J. M., & Cory, S. (2018). The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene, 26(9), 1324-1337.
Chabner, B. A., & Roberts, T. G. (2005). Timeline: Chemotherapy and the war on cancer. Nature Reviews Cancer, 5(1), 65-72.
Chen, L., Jenjaroenpun, P., Pillai, A. M., Ivshina, A. V., & Ow, G. S. (2019). Next-generation sequencing in cancer diagnostics. Theranostics, 9(20), 5732-5752.
Das, S., & Jena, P. K. (2020). Nanotechnology in cancer: Therapeutic applications and developments. Current Drug Metabolism, 21(7), 535-541.
Druker, B. J., & Lydon, N. B. (2000). Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. Journal of Clinical Investigation, 105(1), 3-7.
FDA. (2021). Biomarker Qualification: Evidentiary Framework. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-development-toolddt- qualification-programs/biomarker-qualificationevidentiary- framework
Garber, K. (2018). Alnylam launches era of RNAi drugs. Nature Biotechnology, 36(9), 777-778.
Hotez, P. J., & Bottazzi, M. E. (2019). COVID-19 mRNA vaccines—A new era in vaccinology. Nature Reviews Drug Discovery, 19(4), 261-263.
Kaelin Jr, W. G. (2019). The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nature Reviews Cancer, 8(11), 865-873.
Letai, A., Sorcinelli, M. D., Beard, C., Korsmeyer, S. J., & Hieter, P. (1999). BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood, 111(4), 2300-2309.
Li, L., & Kaplan, J. (2019). The emerging role of iron in infectious diseases. Microbes and Infection, 21(8-9), 353-361.
Loeb, K. R., & Loeb, L. A. (2000). Significance of multiple mutations in cancer. Carcinogenesis, 21(3), 379-385.
Nussinov, R., & Jang, H. (2019). Dynamic protein assemblies: Chemomechanical coupling in allosteric machines. Trends in Biochemical Sciences, 44(5), 413- 424.
O’Connor, R., & O’Sullivan, G. C. (2013). Targeting the PI3-kinase/Akt/mTOR signalling pathway in cancer. Biochemical Pharmacology, 85(7), 875-887.
Schork, N. J. (2015). Personalized medicine: Time for one-person trials. Nature, 520(7549), 609-611.
Schuh, A., Becq, J., Humphray, S., Alexa, A., Burns, A., Clifford R & Campo, E. (2012). Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood, 120(20), 4191-4196.
Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., ... & Laudanski, K. (2013). Genomic responses in mouse models poorly mimic human inflammatory diseases. Proceedings of the National Academy of Sciences, 110(9), 3507-3512.
Swinney, D. C., & Anthony, J. (2011). How were new medicines discovered?. Nature Reviews Drug Discovery, 10(7), 507-519.
Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y. J., Clifford, S. C., ... & Pfister, S. M. (2012). Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica, 123(4), 465-472.
Weber, G. F., & Bjerke, M. A. (2019). Dealing with the Dilemma of Personalized Medicine in Cancer: Does One Size Fits All?. Frontiers in Oncology, 9, 154. https://doi. org/10.3389/fonc.2019.00154
Copyright (c) 2023 Journal of Advanced Research in Biochemistry and Pharmacology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
We, the undersigned, give an undertaking to the following effect with regard to our article entitled
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-
1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.
3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.
4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.
5. I/We also agree to the authorship of the article in the following sequence:-
Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________
(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.
(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.
(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.